{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:45:00Z","timestamp":1775666700401,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.pcad.2019.12.007","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T19:52:41Z","timestamp":1577389961000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Renal denervation: Alternative treatment options for hypertension?"],"prefix":"10.1016","volume":"63","author":[{"given":"Aashish","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marloe","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamunoinemi","family":"Bob-Manuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Stephen","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2019.12.007_bb0005","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.2017.18209","article-title":"The 2017 clinical practice guideline for high blood pressure","volume":"318","author":"Whelton","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2019.12.007_bb0010","first-page":"1","article-title":"Hypertension among adults in the United States, 2009\u20132010","author":"Yoon","year":"2012","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.pcad.2019.12.007_bb0015","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2019.12.007_bb0020","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2019.12.007_bb0025","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2019.12.007_bb0030","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/CIRCULATIONAHA.112.097345","article-title":"Resistant hypertension: incidence, prevalence, and prognosis","volume":"125","author":"Pimenta","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2019.12.007_bb0035","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2019.12.007_bb0040","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2019.12.007_bb0045","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","article-title":"Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008","volume":"124","author":"Egan","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2019.12.007_bb0050","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","article-title":"Prevalence of resistant hypertension in the United States, 2003\u20132008","volume":"57","author":"Persell","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2019.12.007_bb0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/HYPERTENSIONAHA.114.03565","article-title":"Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study","volume":"64","author":"Diaz","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2019.12.007_bb0060","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2215\/CJN.00550113","article-title":"Prevalence of apparent treatment-resistant hypertension among individuals with CKD","volume":"8","author":"Tanner","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pcad.2019.12.007_bb0065","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2016.05.044","article-title":"Lack of control of hypertension in primary cardiovascular disease prevention in Europe: results from the EURIKA study","volume":"218","author":"Borghi","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2019.12.007_bb0070","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la Sierra","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2019.12.007_bb0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the Chronic Renal Insufficiency Cohort Study","volume":"67","author":"Thomas","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2019.12.007_bb0080","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.113.01448","article-title":"Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network","volume":"62","author":"Egan","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2019.12.007_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104362","article-title":"Resistant hypertension, patient characteristics, and risk of stroke","volume":"9","author":"Hung","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pcad.2019.12.007_bb0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jash.2014.03.003","article-title":"Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality","volume":"8","author":"Irvin","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.pcad.2019.12.007_bb0095","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2015.142","article-title":"Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension","volume":"88","author":"Sim","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2019.12.007_bb0100","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/HJH.0000000000000023","article-title":"Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study","volume":"32","author":"Tsioufis","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.pcad.2019.12.007_bb0105","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/jch.12773","article-title":"Blood pressure control provides less cardiovascular protection in adults with than without apparent treatment-resistant hypertension","volume":"18","author":"Egan","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.pcad.2019.12.007_bb0110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1161\/01.HYP.5.1.86","article-title":"Plasma catecholamines and essential hypertension. An analytical review","volume":"5","author":"Goldstein","year":"1983","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2019.12.007_bb0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1161\/01.HYP.14.2.177","article-title":"Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings","volume":"14","author":"Anderson","year":"1989","journal-title":"Hypertension"},{"issue":"suppl 1","key":"10.1016\/j.pcad.2019.12.007_bb0120","first-page":"75","article-title":"Regional norepinephrine turnover in human hypertension","volume":"11","author":"Esler","year":"1989","journal-title":"Clin Exp Hypertens A"},{"key":"10.1016\/j.pcad.2019.12.007_bb0125","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","article-title":"Sympathetic overactivity in patients with chronic renal failure","volume":"327","author":"Converse","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2019.12.007_bb0130","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00000658-194111440-00018","article-title":"Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension","volume":"114","author":"Grimson","year":"1941","journal-title":"Ann Surg"},{"key":"10.1016\/j.pcad.2019.12.007_bb0135","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/jama.1946.02870080001001","article-title":"The surgical treatment of arterial hypertension","volume":"130","author":"Peet","year":"1946","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2019.12.007_bb0140","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/jama.1953.03690160001001","article-title":"Splanchnicectomy for essential hypertension; results in 1,266 cases","volume":"152","author":"Smithwick","year":"1953","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2019.12.007_bb0145","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.transproceed.2010.04.014","article-title":"It takes time after bilateral nephrectomy for better control of resistant hypertension in renal transplant patients","volume":"42","author":"Gawish","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.pcad.2019.12.007_bb0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijscr.2015.08.001","article-title":"Bilateral native nephrectomy for refractory hypertension in kidney transplant and kidney pancreas transplant patients","volume":"15","author":"Lerman","year":"2015","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.pcad.2019.12.007_bb0155","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/bmj.3.5871.78","article-title":"Hypertension in renal transplant recipients: role of bilateral nephrectomy","volume":"3","author":"Cohen","year":"1973","journal-title":"Br Med J"},{"key":"10.1016\/j.pcad.2019.12.007_bb0160","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/archsurg.1983.01390100064016","article-title":"Selective posttransplantation bilateral native nephrectomy. Indications and results","volume":"118","author":"Castaneda","year":"1983","journal-title":"Arch Surg"},{"key":"10.1016\/j.pcad.2019.12.007_bb0165","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00007890-198808000-00009","article-title":"Antihypertensive effect of beta blockade in renal transplant recipients with or without host kidneys","volume":"46","author":"Huysmans","year":"1988","journal-title":"Transplantation"},{"key":"10.1016\/j.pcad.2019.12.007_bb0170","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.jacc.2015.08.018","article-title":"Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation","volume":"66","author":"Mahfoud","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2019.12.007_bb0175","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00270-013-0796-7","article-title":"Chemical renal denervation in the rat","volume":"37","author":"Consigny","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.pcad.2019.12.007_bb0180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.carrev.2015.04.008","article-title":"Next generation renal denervation: chemical \u201cperivascular\u201d renal denervation with alcohol using a novel drug infusion catheter","volume":"16","author":"Fischell","year":"2015","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.pcad.2019.12.007_bb0185","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.atherosclerosis.2017.04.022","article-title":"Safety and performance of the second generation EnligHTN Renal Denervation System in patients with drug-resistant, uncontrolled hypertension","volume":"262","author":"Worthley","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2019.12.007_bb0190","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.4244\/EIJY14M12_01","article-title":"Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study","volume":"10","author":"Sievert","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2019.12.007_bb0195","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.carrev.2013.02.004","article-title":"Sympathetic renal denervation: hypertension beyond SYMPLICITY","volume":"14","author":"Barbash","year":"2013","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.pcad.2019.12.007_bb0200","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jcin.2015.11.041","article-title":"Transcatheter alcohol-mediated perivascular renal denervation with the Peregrine System: first-in-human experience","volume":"9","author":"Fischell","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2019.12.007_bb0205","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4244\/EIJV9I6A118","article-title":"Beta radiation for renal nerve denervation: initial feasibility and safety","volume":"9","author":"Waksman","year":"2013","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2019.12.007_bb0210","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study","volume":"373","author":"Krum","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2019.12.007_bb0215","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial","volume":"376","author":"Symplicity HTNI","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2019.12.007_bb0220","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","article-title":"Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial","volume":"385","author":"Azizi","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2019.12.007_bb0225","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1093\/eurheartj\/eht197","article-title":"Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial","volume":"34","author":"Worthley","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2019.12.007_bb0230","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2019.12.007_bb0235","first-page":"E105","article-title":"Comparison of two different radiofrequency ablation systems for renal artery denervation: evaluation of short-term and long-term follow up","volume":"93","author":"Al Raisi","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2019.12.007_bb0240","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurheartj\/ehu441","article-title":"Predictors of blood pressure response in the SYMPLICITY HTN-3 trial","volume":"36","author":"Kandzari","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2019.12.007_bb0245","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/HYPERTENSIONAHA.115.05283","article-title":"Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension","volume":"65","author":"Desch","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2019.12.007_bb0250","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/HJH.0000000000000977","article-title":"Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial","volume":"34","author":"Mathiassen","year":"2016","journal-title":"J Hypertens"},{"key":"10.1016\/j.pcad.2019.12.007_bb0255","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2019.12.007_bb0260","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial","volume":"390","author":"Townsend","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2019.12.007_bb0265","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2019.12.007_bb0270","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2018.12.082","article-title":"Sham-controlled randomized trials of catheter-based renal denervation in patients with hypertension","volume":"73","author":"Sardar","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2019.12.007_bb0275","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCULATIONAHA.118.037654","article-title":"A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN)","volume":"139","author":"Fengler","year":"2019","journal-title":"Circulation"},{"issue":"42","key":"10.1016\/j.pcad.2019.12.007_bb0280","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1093\/eurheartj\/ehz118","article-title":"Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry","volume":"40","author":"Mahfoud","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2019.12.007_bb0285","unstructured":"Lobo M, Worthley SG. IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN (EnligHTN-II)."},{"key":"10.1016\/j.pcad.2019.12.007_bb0290","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jacc.2012.05.036","article-title":"A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension","volume":"60","author":"Pokushalov","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2019.12.007_bb0295","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.hrthm.2014.03.055","article-title":"Renal denervation for improving outcomes of catheter ablation in patients with atrial fibrillation and hypertension: early experience","volume":"11","author":"Pokushalov","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.pcad.2019.12.007_bb0300","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/jhh.2014.91","article-title":"Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study","volume":"29","author":"Gal","year":"2015","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pcad.2019.12.007_bb0305","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","article-title":"Resistant hypertension? Assessment of adherence by toxicological urine analysis","volume":"31","author":"Jung","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.pcad.2019.12.007_bb0310","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.carrev.2018.02.016","article-title":"Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency","volume":"19","author":"Lauder","year":"2018","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.pcad.2019.12.007_bb0315","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2310\/6670.2007.00024","article-title":"Acute device-based blood pressure reduction: electrical activation of the carotid baroreflex in patients undergoing elective carotid surgery","volume":"15","author":"Schmidli","year":"2007","journal-title":"Vascular"},{"key":"10.1016\/j.pcad.2019.12.007_bb0320","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jacc.2010.03.089","article-title":"Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study","volume":"56","author":"Scheffers","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2019.12.007_bb0325","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial","volume":"58","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2019.12.007_bb0330","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jash.2012.04.004","article-title":"Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial","volume":"6","author":"Hoppe","year":"2012","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.pcad.2019.12.007_bb0335","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/S0140-6736(17)32337-1","article-title":"Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study","volume":"390","author":"Spiering","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2019.12.007_bb0340","unstructured":"Williams B, Stone GW. CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD\u2122 (CALM-2)."}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062019301677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062019301677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:16:47Z","timestamp":1758500207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062019301677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0033062019301677"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2019.12.007","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal denervation: Alternative treatment options for hypertension?","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2019.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}